ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
16 Jan 2025 19:51

Canvest (1381 HK): Attractive Spread with Steady Progress in Precondition Satisfaction

Grandblue continues to progress toward satisfying the precondition, having secured NDRC approval. The remaining regulatory approvals required are...

Logo
1.3k Views
Share
bullishAvjennings Ltd
15 Jan 2025 09:02

AVJennings (AVJ AU): Ho Bee's Superior Proposal

Although terms are indicative, buy  a tick or three below Ho Bee's terms. You could also consider buying the Singaporean leg (quoted in AUD), and...

Logo
482 Views
Share
13 Jan 2025 10:38

Insignia Financial (IFL AU): Bain Calls CC Capital's $4.30/Share NBIO

Both Offers are non-binding. IFL may hold out for more, but they should engage here. However, I'm still not confident Tanarra is willing to kick...

Logo
405 Views
Share
13 Jan 2025 06:15

Smart Share Global (EM US)'s MBO NBIO

Should a defintive agreement be inked, this is done. The risk to the trade, as with many US-listed China plays, is one of timing. Trading at a...

Logo
374 Views
Share
bullishESR Group
13 Jan 2025 01:34

Merger Arb Mondays (13 Jan) - ESR, Henlius, Goldlion, Canvest, 7&I, Fujitsu General, Pressance

This week, the highest gross spreads are Smart Share (26.3%), Pressance (22.1%), Seven & I (15.2%), Get Nice Financial (9.9%), ESR (8.3%), Goldlion...

Logo
674 Views
Share
x